|
|
330 Cochrane Drive
Markham, Ontario L3R 8E4 Canada
phone:(905) 479-5306
fax:(905) 479-1287
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
1996 |
| Employees |
55 |
|
|
| www.cytochroma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD) |
|
| Management |
| Charles W. Bishop, PhD President and Chief Executive Officer;
Bruce McCarty, MBA Executive Director, Manufacturing Operations;
Joel Z. Melnick, MD Vice President, Clinical Research and Development;
Eric J. Messner, MBA Chief Operating Officer;
Gordon Ngan, CFA, MBA Executive Director, Corporate Development;
Mojtaba Noursalehi, PhD Executive Director, Biometrics
P. Martin Petkovich, PhD Chief Scientific Officer;
Jay White, PhD Vice President, Product Development |
| |
|
|
| |
|
| Keywords |
| small molecule, signaling, metabolism, enzyme, cytochrome |
|
|
|
| Description |
|
Cytochroma Inc. is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. |
|
| Products / Services |
Cytochroma has three lead product candidates in development for CKD patients' CTA018 Injection and CTAP201 Injection for the treatment of SHPT and CTAP101 Capsules for the treatment of vitamin D insufficiency. The Company's lead products address a significant need for new therapeutic options to better control these disorders and their associated morbidities such as endocrine, cardiovascular, and bone and mineral diseases. Cytochroma's vitamin-D based therapeutics address target markets projected to reach more than $1.4 billion annually by 2013 in the U.S.
|
|
| Technology / Differentiation |
| Cytochroma's expertise in vitamin D chemistry, biochemistry, metabolism and physiology, combined with its experience in bringing vitamin D-based therapeutics to market uniquely positions the Company to improve the lives of CKD patients suffering from diseases related to vitamin D insufficiency and SHPT. |
|
| Market / Customers |
The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD.
|
|
| Status |
| Phase II |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members